These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28527855)

  • 1. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable pharmacotherapy for opioid use disorders (IPOD).
    Farabee D; Hillhouse M; Condon T; McCrady B; McCollister K; Ling W
    Contemp Clin Trials; 2016 Jul; 49():70-7. PubMed ID: 27282118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
    Gordon MS; Kinlock TW; Vocci FJ; Fitzgerald TT; Memisoglu A; Silverman B
    J Subst Abuse Treat; 2015 Dec; 59():52-8. PubMed ID: 26299956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
    Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
    Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
    Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
    Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release naltrexone for opioid use disorder started during or following incarceration.
    Lincoln T; Johnson BD; McCarthy P; Alexander E
    J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
    Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
    J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
    Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
    Friedmann PD; Wilson D; Nunes EV; Hoskinson R; Lee JD; Gordon M; Murphy SM; Bonnie RJ; Chen DT; Boney TY; O'Brien CP
    J Subst Abuse Treat; 2018 Feb; 85():61-65. PubMed ID: 28236511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
    Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
    BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.